Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-96345 SCHEMBL5419354 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5077901 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL29386897 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5673687 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL1447963 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5419344 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5378537 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL675160 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| Cp-96345 SCHEMBL5419350 | 1.00 | TACR1 (1.00) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL9743556 | 0.95 | TACR1 (0.90) | TACR1CACNA1FCHRM5CACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | claimed |
| US-20010006972-A1 | NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SYMPTOMS OF IRRITABLE BOWEL SYNDROME | WILLIAMS STEPHEN A (US) | 2001-07-05 | — | — | US | claimed |
| US-6254585-B1 | Surgical irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS, INC. | 2001-07-03 | — | — | US | claimed |
| EP-0659409-A2 | Substance 1 antagonists for the inhibition of angiogenesis | PFIZER INC. (US) | 1995-06-28 | — | — | EP | claimed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | disclosed |
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-04 | — | — | US | disclosed |
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-04 | — | — | US | disclosed |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220175797-A1 | OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD | OMEROS CORP (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| EP-0799051-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN, INFLAMMATION AND SPASM | OMEROS MEDICAL SYSTEMS, INC (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019233-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN, INFLAMMATION AND SPASM | OMEROS MEDICAL SYSTEMS, INC. (US) | 1996-06-27 | — | — | WO | disclosed |
| EP-0659409-A2 | Substance 1 antagonists for the inhibition of angiogenesis | PFIZER INC. (US) | 1995-06-28 | — | — | EP | disclosed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994004496-A9 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | — | 1995-01-26 | — | — | WO | disclosed |
| WO-1994004496-A1 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | PFIZER INC. (US) | 1994-03-03 | — | — | WO | disclosed |
| EP-0566589-A1 | N-ALKYL QUINUCLIDINIUM SALTS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1993-10-27 | — | — | EP | disclosed |
| WO-1992012151-A1 | N-ALKYL QUINUCLIDINIUM SALTS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006972-A1 | NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SYMPTOMS OF IRRITABLE BOWEL SYNDROME | TACR1, TACR2, VIPR1 | TACR1 1/4885CACNA1F 779/4885CHRM5 356/4885 |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885CACNA1F 484/4885CHRM5 35/4885 |
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | KIT, TACR1, MRGPRX2 | TACR1 2/4885CACNA1F 1861/4885CHRM5 779/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR1 226/4885CACNA1F 484/4885CHRM5 35/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885CACNA1F 484/4885CHRM5 35/4885 |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | TACR1 12/4885CACNA1F 2535/4885CHRM5 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.